Psychiatric Outpatient Visit Note (US)
Session Note Template:
A standard psychiatric outpatient note that can be used to support CPT codes (99214, 99204) for medical prescribers (Psychiatrists, Psychiatric Advanced Practice Providers) typically used for medication management of new or existing patients. It covers history of presenting information, functional assessment, medical system review, medication, medical history, substance use, risk assessment, any clinical assessments, labs, interventions, assessment with medical necessity justification, references to risks/benefits counseling, prescription drug monitoring program, and plan. This template can be used by prescribers for evaluation and management for medication and if applicable additional psychotherapy in NovoNote, NovoPsych’s AI scribe for clinicians.
Visit Information
- Setting and Location: In-person or by telehealth.
- Date of Service: MM/DD/YYYY
- Informants and Records Reviewed: Collateral information, and any records reviewed.
- Consent and Confidentiality: Informed consent, telehealth consent and any release of information, only if discussed.
- Age and Gender: In years, Gender stated
Reason for Consultation
- Chief Complaint: Why the patient came in, whether they are a new or established patient, and their symptoms and goals in their own words.
- History of Presenting Illness: Symptoms, frequency, severity, onset, and any changes from previous session(s) when applicable
- Past Psychiatric History: Past diagnoses, symptoms and treatments related to the current presenting problems.
- Functional Assessment: Functioning at work, school, home, in relationships and in self-care, and any changes since the last visit.
Symptom Checklist/Review of Systems
If a category has no symptoms, it says “None reported.”
- Psychiatric: Mood, anxiety, trauma and perceptual symptoms reported.
- Constitutional & Somatic: Energy, sleep, weight, appetite and physical symptoms reported.
- Neurological: Tremor, involuntary movements, headaches, dizziness or cognitive changes reported.
- Endocrine & Metabolic: Heat or cold intolerance, thirst or frequent urination reported.
Risk
Current risk items highlighted in red.
- Suicidal Ideation: Ideation, intent, plan, means, preparatory behavior, deterrents and reasons for living.
- Self-Harm: Urges and behavior.
- Homicidal Ideation or Harm to Others: Ideation, intent, plan and any identified target.
- Violence and Aggression: Urges, threats and behavior.
- Access to Means: Firearms, stockpiled medications or other means, and any restriction agreed.
- Warning Signs: Signs that the patient is getting worse.
- Protective Factors: Supports, reasons for living and engagement in treatment.
- Risk Management: Safety planning, crisis resources discussed (including 988 and 911) and actions taken to reduce risk.
Mental Status Examination
- Appearance: Grooming, dress and physical presentation as observed
- Behavior: Activity level, cooperation, eye contact and any notable behaviors as observed
- Speech: Rate, rhythm, volume and tone as observed
- Mood: Patient’s reported mood, using their own words where possible
- Affect: Range, congruence and appropriateness as observed, noting any discrepancy with the stated mood
- Thought Process: Organization, coherence and goal-direction
- Thought Content: Preoccupations, delusions and intrusive thoughts, recording unwanted thoughts the patient finds distressing and rejects in the patient’s own terms
- Perception: Reported hallucinations or sensory misinterpretations, with type and impact
- Cognition: Memory, orientation, concentration and comprehension
- Insight: Patient’s understanding of their own condition and treatment
- Judgment: Patient’s decision-making ability and understanding of consequences
Medication Review
- Current Medications: Name, dose, route, frequency and prescriber for each medication.
- Changes This Session: Any medication started, increased, decreased, held, stopped or refilled, and why.
- Side Effects: What was reported, how severe it was and how it was managed.
- Adherence: How the patient takes the medication, missed doses and barriers.
- Allergies: Drug allergies, or no known drug allergies.
Past Medical History
- Prior Medical History: Past diagnoses, illnesses, surgeries and hospitalizations.
- Prior Medication: Past medication trials, doses, benefits and why they were stopped.
Sleep:
Falling asleep, staying asleep, early waking, total hours, quality and how medication affects sleep.
Appetite and Nutrition:
Appetite changes, weight changes, eating patterns and nutrition advice given.
Substance Use:
Only the substances raised from the following: alcohol, tobacco and nicotine, cannabis, stimulants, opioids, sedatives, hallucinogens, caffeine and other. Includes current use, changes, cravings, withdrawal and interactions with prescribed medication.
Clinical Assessments Administered:
Any administered measure’s name, score, severity band, date and change from the last score.
Assessment:
Summary of symptoms, functioning, medication efficacy, tolerance, and additional current stressors and supports.
Diagnoses:
Diagnoses the clinician named, with DSM-5-TR and ICD-10-CM codes, plus any rule-outs or differentials.
Medical Necessity:
Why prescriber-level evaluation and management was needed, and what continued treatment aims to achieve.
Interventions, Psychoeducation and Supportive Therapy:
What the clinician explained, taught or reinforced, and how the patient responded.
Treatment Plan:
Included only if the source contains one.
Prescription Drug Monitoring Program:
Whether the PDMP was checked
Plan:
A numbered list of medication actions, labs and monitoring, referrals, psychotherapy, lifestyle advice, safety steps and any options the patient declined.
Risks and Benefits of Medication Counseling:
Counseling on the risks, benefits, side effects and importance of taking medication consistently.
Follow-Up:
When the next visit is, and when the patient should get in touch sooner.
Visit Information
- Setting and Location: In person, 11 NovoNote Street, Suite 200, Austin, TX 78701
- Date of Service: September 8, 2026
- Informants and Records Reviewed: Patient; PHQ-9 and GAD-7 results from July 14, 2026
- Age: 34 years
- Gender: Female
Reason for Consultation
Chief Complaint:
- Established patient here for medication follow-up
- Emma reports she is “doing a bit better, but still not myself” and wants to “get back to enjoying things”
History of Presenting Illness:
- Emma reports her mood has improved a little since sertraline was increased to 100 mg eight weeks ago
- She has ongoing low motivation and worries most days, mostly about work
- She reports two panic episodes in the past month, down from weekly
Past Psychiatric History:
- First depressive episode at age 22, treated with fluoxetine
- No psychiatric hospitalizations or suicide attempts
Functional Assessment:
- Working full time as an accountant; reports reduced concentration and missing two deadlines
- Has pulled back from weekend social plans; relationship with partner is supportive
Symptom Checklist/Review of Systems
Psychiatric:
- Low mood, reduced interest, excessive worry, panic episodes
Constitutional & Somatic:
- Fatigue, early morning waking, reduced appetite
Neurological:
- None reported
Endocrine & Metabolic:
- None reported
Risk
- Suicidal Ideation: Denied. Emma said, “No, I don’t have any thoughts of ending my life.”
- Self-Harm: Denied.
- Homicidal Ideation or Harm to Others: Denied.
- Violence and Aggression: None reported.
- Access to Means: No firearms at home; medications kept in a locked cabinet.
- Warning Signs: Emma named staying in bed on weekends and avoiding friends as early signs of getting worse.
- Protective Factors: Supportive partner, stable job, engaged in treatment.
- Risk Management: Safety plan reviewed; 988 and 911 discussed.
Mental Status Examination
- Appearance: Well groomed and dressed appropriately.
- Behavior: Cooperative with good eye contact.
- Speech: Normal rate and volume.
- Mood: “Flat, but better than before.”
- Affect: Mildly restricted and congruent with mood.
- Thought Process: Logical and goal directed.
- Thought Content: Preoccupied with work performance; no delusions.
- Perception: No hallucinations reported.
- Cognition: Alert and oriented; reports reduced concentration.
- Insight: Good.
- Judgment: Good.
Medication Review
Current Medications:
- Sertraline 100 mg oral daily
- Clonazepam 0.5 mg oral as needed for panic, up to once daily
- Levothyroxine 50 mcg oral daily (prescribed by primary care provider)
Changes This Session:
- Sertraline increased to 150 mg daily because of partial response
Side Effects:
- Mild nausea in the first week after the last increase, now resolved
Adherence:
- Missed two sertraline doses while traveling; no other barriers reported
Allergies:
- Penicillin (rash)
Past Medical History
Prior Medical History:
- Hypothyroidism, diagnosed 2021
Prior Medication:
- Fluoxetine 20 mg, stopped because of sexual side effects
Sleep:
- Falls asleep without difficulty; wakes at 4:00 am three to four nights a week; about six hours a night
Appetite and Nutrition:
- Reduced appetite; weight 138 lbs, down from 142 lbs at the last visit
Substance Use
- Alcohol: Two to three glasses of wine on weekends, down from nightly; counseled on interaction with clonazepam
- Caffeine: Two cups of coffee each morning
Clinical Assessments Administered
- PHQ-9: 14 (moderate), down from 18 on July 14, 2026
- GAD-7: 11 (moderate), down from 15 on July 14, 2026
Assessment:
- Emma has recurrent depression and generalized anxiety that have partly responded to sertraline 100 mg. PHQ-9 and GAD-7 scores have improved, but symptoms still affect her work and social life. She tolerates sertraline well. Clonazepam use is appropriate and not increasing. Supports are stable.
Diagnoses:
- Major depressive disorder, recurrent episode, moderate (F33.1)
- Generalized anxiety disorder (F41.1)
Medical Necessity:
- Prescriber-level evaluation was needed to assess partial response, adjust antidepressant dosing and monitor benzodiazepine use. Continued treatment aims to achieve remission and restore full functioning at work.
Interventions, Psychoeducation and Supportive Therapy:
- Explained how long a dose increase takes to work and the side effects to watch for
- Reviewed sleep hygiene and cutting back on alcohol
- Emma engaged well and agreed with the plan
Prescription Drug Monitoring Program:
- PDMP checked; results match the prescribed clonazepam, with no other controlled substances found
Plan:
- Increase sertraline to 150 mg oral daily; prescription sent, 30 tablets, two refills
- Continue clonazepam 0.5 mg as needed; no refill needed this visit
- Repeat PHQ-9 and GAD-7 at the next visit
- Referral to individual therapy (CBT) provided
- Keep alcohol to weekends and avoid it on days she takes clonazepam
- Follow the safety plan; call 988 or 911 if symptoms get worse
Risks and Benefits of Medication Counseling:
- Emma was counseled on the risks and benefits of sertraline and clonazepam, including possible side effects and the importance of taking them consistently.
Follow-Up:
- October 6, 2026 at 10:30 am; contact the office sooner if mood gets worse or side effects appear
- Template Type
- Session Note
- Assessment Session
Author:
Dr Liz Rojas
Share
What NovoNote Users Say
See how mental health professionals have transformed their practice with NovoNote.